{"entity":{"id":"paper-huang-bone-marrow-transplant","kind":"paper","name":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","aka":[],"tldr":"Paper cited by one institution page, indexed on Europe PMC as PubMed record 16883312 and published in Bone marrow transplantation; the citing page links this DOI, which is how the record was matched.","summary":"Many patients who require allogeneic hematopoietic stem cell transplantation (allo-HSCT) lack a human leukocyte antigen (HLA)-matched donor. Here, we report a protocol for haploidentical allo-HSCT that combines granulocyte-colony stimulating factor primed bone marrow (G-BM) and peripheral blood stem cells (PBSC) without in vitro T-cell depletion (TCD). In this study, 171 patients, including 86 in high-risk group, underwent transplantation from haploidentical family donors. All patients achieved sustained, full donor chimerism. One hundred and eleven patients were alive in remission at a median of 682 (253-1502) days. The cumulative incidence of grade III-IV acute graft-versus-host disease (GVHD) was 23% and that of extensive chronic GVHD, 47%; these were not influenced by HLA disparity. Patients younger than 15 years had less grade III-IV acute GVHD than older patients (P=0.044). The 2-year probability of relapse was 12% for standard-risk disease and 39% for high-risk disease. The 2-year probability of leukemia-free survival (LFS) was 68% for standard-risk patients and 42% for high-risk patients (P=0.0009). Grade III-IV acute GVHD was associated with better LFS (P=0.0017). The results require confirmation and show that G-BM combined with PBSC from haploidentical family donors, without in vitro TCD, may be used as a good source of stem cells for allo-HSCT.\n\nIndexed on Europe PMC as PubMed record 16883312 (DOI 10.1038/sj.bmt.1705445). Matched by DOI alone: one institution page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Bone Marrow Transplant 2006","url":"https://doi.org/10.1038/sj.bmt.1705445"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/16883312/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/16883312"}],"tags":["europepmc-ingest"],"related":["pku-peoples-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Bone marrow transplantation","year":2006,"doi":"10.1038/sj.bmt.1705445","pmid":"16883312","authors":"Huang XJ, Liu DH, Liu KY, et al.","paperType":"observational","findings":[],"whatItMeans":"One institution page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.","caveats":["Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-huang-bone-marrow-transplant/","neighbours":{"institution":[{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","route":"/institutions/pku-peoples-hospital/"}]}}